Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Nature Genetics

• Publication date

  2012-09-02

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/ng.2396PMID 22941188PMCID PMC4915822
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

  2012cited by this paper
• RET, ROS1 and ALK fusions in lung cancer

  2012cited by this paper
• ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

  2012cited by this paper
• CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia

  2012cited by this paper
• ROS1 rearrangements define a unique molecular class of lung cancers.

  2012cited by this paper
• Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer

  2012cited by this paper
• KIF5B-RET fusions in lung adenocarcinoma

  2012cited by this paper
• The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma.

  2011cited by this paper
• Nuclear factor I/B is an oncogene in small cell lung cancer.

  2011cited by this paper
• Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung.

  2011cited by this paper
• A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer.

  2011cited by this paper
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• Frequent mutation of histone modifying genes in non-Hodgkin lymphoma

  2011cited by this paper
• CREBBP mutations in relapsed acute lymphoblastic leukaemia

  2011cited by this paper
• Initial genome sequencing and analysis of multiple myeloma

  2011cited by this paper
• Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

  2011cited by this paper
• Slit-Robo signaling induces malignant transformation through Hakai-mediated E-cadherin degradation during colorectal epithelial cell carcinogenesis

  2011cited by this paper
• Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens

  2011cited by this paper
• Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

  2011cited by this paper
• Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

  2011cited by this paper
• Lung cancer signatures in plasma based on proteome profiling of mouse tumor models.

  2011cited by this paper
• Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer

  2011cited by this paper
• A crucial requirement for Hedgehog signaling in small cell lung cancer

  2011cited by this paper
• Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma

  2010cited by this paper
• Small cell lung cancer

  2010cited by this paper
• Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors

  2010cited by this paper
• Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

  2010cited by this paper
• Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma

  2010cited by this paper
• Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

  2010cited by this paper
• A comprehensive catalogue of somatic mutations from a human cancer genome

  2010cited by this paper
• CBP/p300 double null cells reveal effect of coactivator level and diversity on CREB transactivation

  2010cited by this paper
• Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft

  2010cited by this paper
• Inactivating mutations of acetyltransferase genes in B-cell lymphoma

  2010cited by this paper
• The genomic complexity of primary human prostate cancer

  2010cited by this paper
• Fragile histidine triad protein: structure, function, and its association with tumorogenesis

  2010cited by this paper
• ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor

  2010cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• SLIT2 attenuation during lung cancer progression deregulates beta-catenin and E-cadherin and associates with poor prognosis.

  2010cited by this paper
• Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma.

  2010cited by this paper
• Lung tumours with neuroendocrine differentiation.

  2009cited by this paper
• SOX2 Is an Amplified Lineage Survival Oncogene in Lung and Esophageal Squamous Cell Carcinomas

  2009cited by this paper
• Modes of p53 regulation.

  2009cited by this paper
• A small cell lung cancer genome reports complex tobacco exposure signatures

  2009cited by this paper
• Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.

  2009cited by this paper
• Mapping short DNA sequencing reads and calling variants using mapping quality scores.

  2008cited by this paper
• The structural basis of protein acetylation by the p300/CBP transcriptional coactivator

  2008cited by this paper
• Progress and challenges in selected areas of tobacco carcinogenesis.

  2008cited by this paper
• Bronchopulmonary neuroendocrine tumors

  2008cited by this paper
• Somatic mutations affect key pathways in lung adenocarcinoma

  2008cited by this paper
• PIK3CA mutations and copy number gains in human lung cancers.

  2008cited by this paper
• Exponential decay of GC content detected by strand-symmetric substitution rates influences the evolution of isochore structure.

  2008cited by this paper
• Life and death decisions by the E2F transcription factors.

  2007cited by this paper
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

  2007cited by this paper
• PLASQ: a generalized linear model-based procedure to determine allelic dosage in cancer cells from SNP array data.

  2007cited by this paper
• Current Status of Second-Line Treatment and Novel Therapies for Small Cell Lung Cancer

  2007cited by this paper
• EGFR mutations in small-cell lung cancers in patients who have never smoked.

  2006cited by this paper
• Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification

  2006cited by this paper
• N-(4-Hydroxyphenyl)retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cells

  2006cited by this paper
• Conditional Knockout Mice Reveal Distinct Functions for the Global Transcriptional Coactivators CBP and p300 in T-Cell Development

  2006cited by this paper
• Origins and selection of p53 mutations in lung carcinogenesis.

  2005cited by this paper
• Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.

  2005cited by this paper
• Mutations and deletions of the CBP gene in human lung cancer.

  2005cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

  2004cited by this paper
• Circular binary segmentation for the analysis of array-based DNA copy number data.

  2004cited by this paper
• Theoretical and practical advances in genome halving

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Loss of CBP causes T cell lymphomagenesis in synergy with p27Kip1 insufficiency.

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website

  2004cited by this paper
• The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases.

  2004cited by this paper
• Polyubiquitination of p53 by a Ubiquitin Ligase Activity of p300

  2003cited by this paper
• SIFT: predicting amino acid changes that affect protein function

  2003cited by this paper
• Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation.

  2003cited by this paper
• Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model.

  2003cited by this paper
• Analysis of genetic stability at the EP300 and CREBBP loci in a panel of cancer cell lines

  2003cited by this paper
• Slit proteins: molecular guidance cues for cells ranging from neurons to leukocytes.

  2002cited by this paper
• Inadequate lung development and bronchial hyperplasia in mice with a targeted deletion in the Dutt1/Robo1 gene

  2001cited by this paper
• Signal transduction in neuronal migration: roles of GTPase activating proteins and the small GTPase Cdc42 in the Slit-Robo pathway.

  2001cited by this paper
• Molecular genetics of small cell lung carcinoma.

  2001cited by this paper
• Functional analysis of the p300 acetyltransferase domain: the PHD finger of p300 but not of CBP is dispensable for enzymatic activity.

  2001cited by this paper
• Regulation of repulsion versus adhesion by different splice forms of an Eph receptor

  2000cited by this paper
• Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.

  2000cited by this paper
• DNA damage activates p53 through a phosphorylation-acetylation cascade.

  1998cited by this paper
• PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers

  1998cited by this paper
• St. Jude Children's Research Hospital.

  1997cited by this paper
• Binding and modulation of p53 by p300/CBP coactivators

  1997cited by this paper
• Synergistic activation of transcription by CBP and p53

  1997cited by this paper
• p300 gene alterations in colorectal and gastric carcinomas.

  1996cited by this paper
• Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations.

  1993cited by this paper
• Activation of myc gene family in human lung carcinomas and during heterotransplantation into nude mice.

  1991cited by this paper
• Variable mutations of the RB gene in small-cell lung carcinoma.

  1990cited by this paper
• Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells.

  1990cited by this paper
• Small-cell lung cancer.

  1980cited by this paper

• Atezolizumab plus platinum-based chemotherapy and etoposide as first-line treatment for metastatic small cell lung cancer: a retrospective multicenter observational study.

  2026cites this paper
• RNA sequencing reveals differential expression of circular RNAs in human small cell lung cancer

  2026cites this paper
• Dual targeting of AMRC12 and Malassezia globosa disrupts MYC liquid condensates-driven nuclear pore complex biogenesis in neuroblastoma

  2026cites this paper
• Spatial transcriptomics reveals molecular heterogeneity and subtype-specific therapeutic targets in small cell lung cancer

  2026cites this paper
• Esophageal neuroendocrine carcinoma: molecular insights, diagnostic advances, and emerging treatment strategies.

  2026cites this paper
• Single-patient single-cell RNA sequencing reveals neuroendocrine predominance and immunosuppression in small-cell lung cancer

  2026cites this paper
• Epigenetic remodeling and apoptotic activation by Chidamide suppress small cell lung cancer in molecularly distinct subtypes

  2026cites this paper
• Case report: ALK inhibitor-induced transformation of ALK fusion-positive lung adenocarcinoma to large cell neuroendocrine carcinoma

  2026cites this paper
• The impact of stratified management of Ki-67 on the prognosis of small-cell lung cancer

  2025cites this paper
• Current insights and barriers in FGFR-mediated signaling in lung cancer.

  2025cites this paper
• Primary de novo Epidermal Growth Factor Receptor Mutant Small Cell Lung Carcinomas: Clinicopathological Study of a Rare Entity Presenting in Treatment-Naïve Setting with Review of Literature

  2025cites this paper
• An organoid library unveils subtype-specific IGF-1 dependency via a YAP–AP1 axis in human small cell lung cancer

  2025cites this paper
• Multi-omic profiling provides insights into the heterogeneity, microenvironmental features, and biomarker landscape of small-cell lung cancer

  2025cites this paper
• Real-world data after introduction of chemoimmunotherapy in patients with extensive-disease small cell lung cancer: A multicenter retrospective study.

  2025cites this paper
• Clinicopathological, Cellular and Molecular Analyses of Pulmonary Neuroendocrine Carcinoma with High Expression of Hepatocyte Nuclear Factor 4 Alpha.

  2025cites this paper
• Proteogenomic Characterization of High-Grade Lung Neuroendocrine Carcinoma Deciphers Molecular Diversity and Potential Biomarkers of Different Histological Subtypes in Chinese Population

  2025cites this paper
• Lethal co-expression intolerance underlies the mutually exclusive expression of ASCL1 and NEUROD1 in SCLC cells

  2025cites this paper
• Ensemble machine learning models for lung cancer incidence risk prediction in the elderly: a retrospective longitudinal study

  2025cites this paper
• Small Cell Lung Cancer Unveiled: Exploring the Untapped Resource of Circulating Tumor Cells-Derived Organoids.

  2025cites this paper
• Polo-like Kinase 1 Inhibitors Demonstrate In Vitro and In Vivo Efficacy in Preclinical Models of Small Cell Lung Cancer

  2025cites this paper
• Exploration of Genetic Variants Associated with Lung Cancer: A Comprehensive Review

  2025cites this paper
• Biomarkers in lung cancer treatment.

  2025cites this paper
• First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial

  2025cites this paper
• Molecular subtyping dictates therapeutic response to anti-PD-L1 immunotherapy in ES-SCLC

  2025cites this paper
• Preoperative immunochemotherapy versus chemotherapy as first-line treatment for patients with stage I–IIIB small-cell lung cancer

  2025cites this paper
• In vivo functional screens reveal KEAP1 loss as a driver of chemoresistance in small cell lung cancer

  2025cites this paper
• Challenges of small cell lung cancer heterogeneity and phenotypic plasticity

  2025influential citation
• PLK1 Inhibitors Exhibit Potent Preclinical Activity in Platinum-Sensitive and Resistant Small Cell Lung Cancer Models

  2025cites this paper
• Tumor Heterogeneity and Plasticity in Small Cell Lung Cancer

  2025cites this paper
• Loss of NOTCH2 creates a TRIM28-dependent vulnerability in small cell lung cancer.

  2025cites this paper
• Comprehensive Genomic Profiling of Small-Cell Lung Cancer Reveals Frequent Potentially Targetable Alterations

  2025cites this paper
• Immunotherapy in Extensive Stage Small-Cell Lung Cancer in First-Line and Second-Line: A Systematic Review and Meta-Analysis.

  2025cites this paper
• EP300 compromises antitumor immunity by increasing SOCS1 expression

  2025cites this paper
• Characterization of the extrinsic and intrinsic signatures and therapeutic vulnerability of small cell lung cancers

  2025cites this paper
• Pathology, molecular biology, medical oncology, and radiotherapy implications of lung neuroendocrine neoplasm classification: a multidisciplinary perspective

  2025cites this paper
• Actin dysregulation induces neuroendocrine plasticity and immune evasion: a vulnerability of small cell lung cancer

  2025cites this paper
• EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer.

  2025cites this paper
• DynaTag for efficient mapping of transcription factors in low-input samples and at single-cell resolution

  2025cites this paper
• Myc family proteins: Molecular drivers of tumorigenesis and resistance in neuroendocrine tumors.

  2025cites this paper
• Advances in adoptive cell therapies in small cell lung cancer

  2025cites this paper
• Baseline retinoblastoma transcriptional corepressor 1 (Rb1) functional inactivation is a pre-requisite but not sufficient for small-cell histological transformation in epidermal growth factor receptor (EGFR) mutant lung adenocarcinomas post-tyrosine kinase inhibitor therapy

  2025cites this paper
• Recent Advances in the Clinical Translation of Small-Cell Lung Cancer Therapeutics

  2025cites this paper
• Single‐Cell RNA Sequencing Reveals the Cellular Origin and Evolution of Small‐Cell Neuroendocrine Carcinoma of the Cervix

  2025influential citation
• Advancement Opportunities and Endeavor of Innovative Targeted Therapies for Small Cell Lung Cancer

  2025cites this paper
• Discovery of Novel 2,4,5-Trisubstituted Pyrimidine Derivatives as Potent and Selective FGFR Inhibitors against Gatekeeper Mutants for the Treatment of NSCLC.

  2025cites this paper
• [New perspectives in the management of small cell bronchial cancer].

  2025cites this paper
• Targeting Oncogenic Signaling Pathways in Lung Cancer: The Emerging Role of Nobiletin, a flavonoid from citrus peel

  2025cites this paper
• Case report: Durable response of immuno-chemotherapy targeting a rare ROS1 fusion-positive extensive-stage SCLC patient after primary resistance to crizotinib

  2025cites this paper
• Unlocking the Radiosensitizing Potential of MYC inhibition in Neuroendocrine Malignancies.

  2025cites this paper
• Metabolic reprogramming signature predicts prognosis and immune landscape in small cell lung cancer: MOCS2 validation and implications for personalized therapy

  2025cites this paper
• Molecular basis and therapeutic implications of binary YAPOn/YAPOff cancer classes

  2025cites this paper
• Pulmonary neuroendocrine neoplasms: the molecular landscape, therapeutic challenges, and diagnosis and management strategies.

  2025cites this paper
• Genomic Profiling of Extensive Stage Small-Cell Lung Cancer Patients Identifies Molecular Factors Associated with Survival

  2025cites this paper
• Preclinical evidence that fibroblast growth factor receptor pathway inhibition by BGJ398 enhances small cell lung cancer response to chemotherapy

  2025cites this paper
• Redefining the Fight Against SCLC: Standards, Innovations, and New Horizons

  2025cites this paper
• Updates on Pulmonary Neuroendocrine Carcinoids: Progress and Perspectives

  2025cites this paper
• FGFR2-IIIc isoform detection reveals prognostic prevalence and a functional link to mesenchymal transition in gastric and gastroesophageal junction cancer

  2025cites this paper
• Molecular mechanisms and therapeutic strategies for small‑cell lung cancer transformation after TKI therapy in EGFR‑mutated lung adenocarcinoma (Review)

  2025cites this paper
• Novel concepts of cell-of origin in neuroendocrine neoplasms

  2025cites this paper
• Neuroendocrine Transformation as a Mechanism of Resistance to Targeted Lung Cancer Therapies: Emerging Mechanisms and Their Therapeutic Implications

  2025cites this paper
• The complex network of p300/CBP regulation: Interactions, posttranslational modifications, and therapeutic implications

  2025cites this paper
• Repurposing Mercaptopurine Through Collateral Lethality to Treat Cancers with Somatic RB1–NUDT15 Loss

  2025cites this paper
• Kleinzelliges Lungenkarzinom: Aktuelle Standards und Perspektiven in der ­Behandlung

  2025cites this paper
• Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer

  2024cites this paper
• Evolutionary trajectories of small cell lung cancer under therapy

  2024cites this paper
• Molecular pathology of small cell lung cancer: Overview from studies on neuroendocrine differentiation regulated by ASCL1 and Notch signaling

  2024cites this paper
• Promises of Protein Kinase Inhibitors in Recalcitrant Small-Cell Lung Cancer: Recent Scenario and Future Possibilities

  2024cites this paper
• Expression patterns and clinical implications of PDL1 and DLL3 biomarkers in small cell lung cancer retrospectively studied: Insights for therapeutic strategies and survival prediction

  2024cites this paper
• Facts and hopes on cancer immunotherapy for small cell lung cancer.

  2024cites this paper
• Lung cancer vaccination from concept to reality: A critical review of clinical trials and latest advances.

  2024cites this paper
• Identification of potential regulatory mechanisms and therapeutic targets for lung cancer

  2024cites this paper
• Extracellular vesicles as tools and targets in therapy for diseases

  2024cites this paper
• Epigenome editing in cancer: Advances and challenges for potential therapeutic options.

  2024cites this paper
• Rictor—A Mediator of Progression and Metastasis in Lung Cancer

  2024cites this paper
• Bromodomain Protein-directed Agents and MYC in Small Cell Lung Cancer.

  2024cites this paper
• Mechanistic insights on the role of competing endogenous RNA regulatory networks (ceRNETs) in small cell lung cancer

  2024cites this paper
• Molecular mechanisms underlying the regulation of tumour suppressor genes in lung cancer.

  2024cites this paper
• Genetic Alterations in Lung Cancer

  2024cites this paper
• Genetically-engineered mouse models of small cell lung cancer: the next generation

  2024cites this paper
• Targeting DHX9 Triggers Tumor-Intrinsic Interferon Response and Replication Stress in Small Cell Lung Cancer

  2024cites this paper
• ES-SCLC Patients with PD-L1+ CTCs and High Percentages of CD8+PD-1+T Cells in Circulation Benefit from Front-Line Immunotherapy Treatment

  2024cites this paper
• Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies.

  2024cites this paper
• The outcomes of different regimens depend on the molecular subtypes of pulmonary large‐cell neuroendocrine carcinoma: A retrospective study in China

  2024cites this paper
• Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study

  2024cites this paper
• Applied models and molecular characteristics of small cell lung cancer

  2024cites this paper
• UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas

  2024cites this paper
• Unveiling the Mechanism of Lurbinectedin’s Action and Its Potential in Combination Therapies in Small Cell Lung Cancer

  2024cites this paper
• Comparative crystal structure analysis of the human EP300 and CBP KIX domains.

  2024cites this paper
• Advances in biomarkers for immunotherapy in small-cell lung cancer

  2024cites this paper
• Tumor architecture and emergence of strong genetic alterations are bottlenecks for clonal evolution in primary prostate cancer.

  2024cites this paper
• Sympathetic Neurons Promote Small Cell Lung Cancer Through the Beta-2 Adrenergic Receptor.

  2024cites this paper
• Increased mTOR activity and RICTOR copy number in small cell lung carcinoma progression.

  2024cites this paper
• ARAF Amplification in Small-Cell Lung Cancer-Transformed Tumors Following Resistance to Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors

  2024cites this paper
• Clinical significance of a prospective large genomic screening for small-cell lung cancer: the genetic classification and a biomarker driven phase II trial of gedatolisib.

  2024cites this paper
• Emerging Role of the p53 Pathway in Modulating Natural Killer Cell Mediated Immunity.

  2024cites this paper
• Small cell lung cancer with liver metastases: from underlying mechanisms to treatment strategies

  2024cites this paper
• Classification histomoléculaire des cancers pulmonaires et de leurs prénéoplasies

  2024cites this paper
• 小细胞肺癌分子分型：向临床实践转化的挑战

  2024cites this paper
• A biomarker exploration in small-cell lung cancer for brain metastases risk and prophylactic cranial irradiation therapy efficacy.

  2024cites this paper
• Long-term effect of supporting immunotherapy in a patient with metastatic small cell lung cancer

  2024cites this paper